Non-familial cardiomyopathies in Lebanon: exome sequencing results for five idiopathic cases

[1]  Ossama K. Abou Hassan,et al.  Clinical and genetic characteristics of pulmonary arterial hypertension in Lebanon , 2018, BMC Medical Genetics.

[2]  Richard P Lifton,et al.  Application of Whole Exome Sequencing in the Clinical Diagnosis and Management of Inherited Cardiovascular Diseases in Adults , 2017, Circulation. Cardiovascular genetics.

[3]  P. Kwok,et al.  Arrhythmogenic Right Ventricular Cardiomyopathy Caused by a Novel Frameshift Mutation. , 2016, Cardiac electrophysiology clinics.

[4]  A. Kimura.  Molecular genetics and pathogenesis of cardiomyopathy , 2015, Journal of Human Genetics.

[5]  M. Link,et al.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat , 2015, Journal of the American College of Cardiology.

[6]  Zhongsheng Sun,et al.  Investigation of Pathogenic Genes in Chinese sporadic Hypertrophic Cardiomyopathy Patients by Whole Exome Sequencing , 2015, Scientific Reports.

[7]  Karen S. Frese,et al.  Atlas of the clinical genetics of human dilated cardiomyopathy. , 2014, European heart journal.

[8]  M. Link,et al.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat , 2015, Journal of the American College of Cardiology.

[9]  P. Elliott,et al.  A straightforward guide to the sarcomeric basis of cardiomyopathies , 2014, Heart.

[10]  L. Al-Shaar,et al.  Primary carnitine deficiency: novel mutations and insights into the cardiac phenotype , 2014, Clinical genetics.

[11]  V. Fuster,et al.  The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. , 2013, Journal of the American College of Cardiology.

[12]  V. Fuster,et al.  The MOGE(S) Classification for a Phenotype-Genotype Nomenclature of Cardiomyopathy: Endorsed by the World Heart Federation. , 2013, Global heart.

[13]  Kenneth L. Jones,et al.  Whole Exome Sequencing Identifies a Troponin T Mutation Hot Spot in Familial Dilated Cardiomyopathy , 2013, PloS one.

[14]  P. Robinson,et al.  Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy , 2013, European Journal of Human Genetics.

[15]  Heidi L Rehm,et al.  Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. , 2013, The Journal of molecular diagnostics : JMD.

[16]  T. Meyer,et al.  Novel mutations in the sarcomeric protein myopalladin in patients with dilated cardiomyopathy , 2012, European Journal of Human Genetics.

[17]  S. Quijano-roy,et al.  Emery-Dreifuss muscular dystrophy, laminopathies, and other nuclear envelopathies. , 2013, Handbook of clinical neurology.

[18]  J. Towbin,et al.  Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. , 2012, Human molecular genetics.

[19]  Juliet A. Ellis,et al.  Novel LMNA mutations in patients with Emery‐Dreifuss muscular dystrophy and functional characterization of four LMNA mutations , 2011, Human mutation.

[20]  H. Calkins,et al.  Gap Junction Remodeling in a Case of Arrhythmogenic Right Ventricular Dysplasia Due to Plakophilin‐2 Mutation , 2008, Journal of cardiovascular electrophysiology.

[21]  M. Komajda,et al.  Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. , 2008, Cardiovascular research.

[22]  G. Nemer,et al.  Exclusive cardiac dysfunction in familial primary carnitine deficiency cases: a genotype–phenotype correlation , 2007, Clinical genetics.

[23]  S. Russell,et al.  Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[24]  R. Hauer,et al.  Plakophilin-2 Mutations Are the Major Determinant of Familial Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2006, Circulation.

[25]  J. Knowles,et al.  Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. , 2002, American journal of physiology. Heart and circulatory physiology.

[26]  E. Ehler,et al.  Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice , 2002, Heart.